Paion Ag (XTER:PA8) Days Payable : 482.15 (As of Jun. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Paion Ag Days Payable?

Paion Ag's average Accounts Payable for the six months ended in Jun. 2023 was €9.44 Mil. Paion Ag's Cost of Goods Sold for the six months ended in Jun. 2023 was €3.57 Mil. Hence, Paion Ag's Days Payable for the six months ended in Jun. 2023 was 482.15.

The historical rank and industry rank for Paion Ag's Days Payable or its related term are showing as below:

XTER:PA8's Days Payable is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 84.43
* Ranked among companies with meaningful Days Payable only.

Paion Ag's Days Payable declined from Jun. 2022 (1,564.90) to Jun. 2023 (482.15). It may suggest that Paion Ag accelerated paying its suppliers.

Paion Ag Days Payable Historical Data

The historical data trend for Paion Ag's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paion Ag Days Payable Chart

Paion Ag Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Days Payable

Get a 7-Day Free Trial

622.29

1,358.51

Paion Ag Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Days Payable	Get a 7-Day Free Trial															1,723.96	401.28	1,564.90	884.74	482.15

Competitive Comparison of Paion Ag's Days Payable

For the Drug Manufacturers - Specialty & Generic subindustry, Paion Ag's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Paion Ag's Days Payable Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Paion Ag's Days Payable distribution charts can be found below:

* The bar in red indicates where Paion Ag's Days Payable falls into.

Paion Ag Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Paion Ag's Days Payable for the fiscal year that ended in Dec. 2022 is calculated as

	Days Payable (A: Dec. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2021 )	+	Accounts Payable (A: Dec. 2022 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2022 )	*	Days in Period
=	( (6.585	+	8.005)	/	2 )	/	1.96	*	365
=	7.295					/	1.96	*	365
=	1,358.51

Paion Ag's Days Payable for the quarter that ended in Jun. 2023 is calculated as:

	Days Payable (Q: Jun. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2022 )	+	Accounts Payable (Q: Jun. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Jun. 2023 )	*	Days in Period
=	( (8.005	+	10.874)	/	2 )	/	3.573	*	365 / 2
=	9.4395					/	3.573	*	365 / 2
=	482.15

Paion Ag Days Payable Related Terms

Thank you for viewing the detailed overview of Paion Ag's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Paion Ag Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Paion Ag (XTER:PA8) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

PAIOF:USA PA8:Germany

Address

Heussstrasse 25, Aachen, DEU, 52078

Website

https://www.paion.com

Paion AG is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.

Executives

Gregor Siebert	Board of Directors
Dr. James Neil Phillips	Board of Directors

Paion Ag Headlines

No Headlines